Prognostic Role of 2-[18F]FDG PET/CT Metabolic Volume Parameters in Patients Affected by Differentiated Thyroid Carcinoma with High Thyroglobulin Level, Negative 131I WBS and Positive 2-[18F]-FDG PET/CT
Open Access
- 25 November 2021
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 11 (12) , 2189
Abstract
The clinical and prognostic role of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography (2-[18F]FDG PET/CT) in the study of patients affected by differentiated thyroid carcinoma (DTC) with positive serum thyroglobulin (Tg) level and negative [131I] whole-body scan ([131I]WBS) has already been demonstrated. However, the potential prognostic role of semi-quantitative PET metabolic volume features, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG), has not yet been clearly investigated. The aim of this retrospective study was to investigate whether the main metabolic PET/CT parameters may predict the prognosis. We retrospectively included 122 patients with a positive 2-[18F]FDG PET/CT for DTC disease after a negative [131I]WBS with Tg > 10 ng/mL. The maximum and mean standardized uptake value (SUVmax and SUVmean), MTV and TLG of the hypermetabolic lesion, total MTV (tMTV) and total TLG (tTLG) were measured for each scan. Progression-free survival (PFS) and overall survival (OS) curves were plotted according to the Kaplan–Meier analysis. After a median follow up of 53 months, relapse/progression of disease occurred in 87 patients and death in 42. The median PFS and OS were 19 months (range 1–132 months) and 46 months (range 1–145 months). tMTV and tTLG were the only independent prognostic factors for OS. No variables were significantly correlated with PFS. The best thresholds derived in our sample were 6.6 cm3 for MTV and 119.4 for TLG. In patients with negative WBS and Tg > 10 ng/mL, 2-[18F]FDG PET/CT metabolic volume parameters (tMTV and tTLG) may help to predict OS.Keywords
This publication has 32 references indexed in Scilit:
- Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Metastatic Differentiated Thyroid CancersClinical Nuclear Medicine, 2015
- Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survivalJournal of Medical Imaging and Radiation Oncology, 2015
- Prognostic Significance of FDG PET/CT on the Follow-Up of Patients of Differentiated Thyroid Carcinoma With Negative 131I Whole-Body Scan and Elevated Thyroglobulin LevelsClinical Nuclear Medicine, 2012
- Positron emission tomography and positron emission tomography‐CT evaluation for recurrent papillary thyroid carcinoma: Meta‐analysis and literature reviewHead & Neck, 2011
- Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?Endocrine-Related Cancer, 2010
- FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0European Journal of Nuclear Medicine and Molecular Imaging, 2009
- F-18 FDG-PET/CT Evaluation of Patients With Differentiated Thyroid Cancer With Negative I-131 Total Body Scan and High Thyroglobulin LevelClinical Nuclear Medicine, 2009
- Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography ScanningThe Journal of Clinical Endocrinology & Metabolism, 2006
- Glucose Transporter 1 Gene Expression is Related to Thyroid Neoplasms with an Unfavorable Prognosis: An Immunohistochemical StudyThyroid®, 2002
- Prognostic Value of[ 18F]Fluorodeoxyglucose Positron Emission Tomographic Scanning in Patients with Thyroid Cancer*The Journal of Clinical Endocrinology & Metabolism, 2000